Eam Investors, LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Eam Investors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$23.5 - $35.38 $937,814 - $1.41 Million	-39,907 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$29.21 - $44.64 $304,105 - $464,747	-10,411 Reduced 20.69%	39,907 $1.29 Million
Q3 2021 Nov 12, 2021	SELL	$21.26 - $38.85 $99,985 - $182,711	-4,703 Reduced 8.55%	50,318 $1.48 Million
Q2 2021 Aug 13, 2021	BUY	$12.56 - $29.69 $691,063 - $1.63 Million	55,021 New	55,021 $1.41 Million

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.